Abstract
To the Editor: Asenapine is a new atypical antipsychotic for the treatment of schizophrenia and acute mania associated with bipolar disorder. The US Food and Drug Administration (FDA) accepted the manufacturer’s New Drug Application (NDA) in November 2007; since asenapine is a fairly new drug, very few data on it are available. The data indicate that it has minimal anticholinergic and cardiovascular side effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
